论文部分内容阅读
目的研究应用放射性碘(~(131)I)治疗分化型甲状腺癌(DTC)对患者肝肾功能的影响。方法收集接受~(131)I治疗的106例DTC患者的临床资料,并根据~(131)I治疗剂量分为低剂量组(≤1.85 GBq,n=19)、中剂量组(2.22 GBq和2.96 GBq,n=50)和高剂量组(≥3.7 GBq,n=37)。对实施~(131)I治疗前后及各组患者的肝肾功能检查结果进行对比分析。结果接受~(131)I治疗前后,67例患者肝功能检查结果记录完整(低剂量组18例,中剂量组37例,高剂量组12例)。与治疗前比较,治疗后总体血清谷草转氨酶(AST)和谷丙转氨酶(ALT)水平升高(P<0.05),但大部分(82.1%)仍在正常范围内。接受~(131)I治疗前后,106例患者均具有完整的肾功能检查结果记录。组内治疗前后患者血尿素氮(BUN)、肌酐(SCr)、尿酸(UA)水平比较,差异均无统计学意义(P>0.05)。结论~(131)I治疗DTC对患者肝肾功能无明显影响,是较为安全的治疗方法。
Objective To study the effect of radioactive iodine (~(131)I) on liver and kidney function in patients with differentiated thyroid cancer (DTC). Methods The clinical data of 106 patients with DTC who received 131I treatment were collected and divided into low dose group (≤1.85 GBq, n=19) and moderate dose group (2.22 GBq and 2.96) according to the (131) I treatment dose. GBq, n = 50) and high dose groups (≥ 3.7 GBq, n = 37). The results of liver and kidney function tests before and after ~(131)I treatment and in each group were compared. RESULTS: Before and after 131I therapy, liver function tests were complete in 67 patients (18 in the low-dose group, 37 in the middle-dose group, and 12 in the high-dose group). Compared with before treatment, the overall serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels increased after treatment (P<0.05), but the majority (82.1%) remained within the normal range. Before and after the (131) I treatment, 106 patients had complete records of renal function tests. There was no significant difference in blood urea nitrogen (BUN), creatinine (SCr), and uric acid (UA) levels before and after treatment in the group (P>0.05). Conclusions ~(131)I treatment of DTC has no significant effect on liver and kidney function in patients. It is a safer treatment.